---
layout: post
title: "Secura Bio, Inc.; Withdrawal of Approval of New Drug Application for FARYDAK (Panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams"
date: 2026-02-05 18:58:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-06182
original_published: 2022-03-24 00:00:00 +0000
significance: 8.00
---

# Secura Bio, Inc.; Withdrawal of Approval of New Drug Application for FARYDAK (Panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 24, 2022 00:00 UTC
**Document Number:** 2022-06182

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for FARYDAK (panobinostat) Capsules, 10 milligrams (mg), 15 mg, and 20 mg, held by Secura Bio, Inc., 1995 Village Center Circle, Suite 128, Las Vegas, NV 89134. Secura Bio, Inc. has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/24/2022-06182/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10)
- API: https://www.federalregister.gov/api/v1/documents/2022-06182

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
